ucb_logo

New epilepsy drug launches in UK

pharmafile | February 29, 2016 | News story | Medical Communications, Research and Development, Sales and Marketing Briviact, UCB Pharma, epilepsy 

UCB Pharma’s Briviact (brivaracetam) has been authorised as an add-on treatment for partial onset seizures (POS), with or without secondary generalised seizures in adults with epilepsy, offering an additional treatment option for UK patients.

In an international Phase III study of 768 patients uncontrolled on their previous medication, Briviact was shown to give significant seizure freedom over placebo, compared with the patients’ usual medication. Patients also revealed the importance of reducing the titration period – which 51% of patients who participated in an independent European treatment satisfaction survey identified as an important goal.

Dr Mark Manford, consultant neurologist at Bedford and Addenbrookes Hospitals, comments: “Finding the right combination of medicines for many epilepsy patients can be a long journey, during which time the patient may continue to suffer seizures and living a normal life is very difficult.  As a neurologist working with patients whose seizures have not yet been brought under control, I welcome the possibility that a new medicine may be able to contribute to the tools available to help my patients.”

The US FDA recently approved Briviact in this same indication, based on trial data in which the drug, when taken with other medications, was shown to be effective in reducing the frequency of seizures

Joel Levy

Related Content

robina-weermeijer-ihfopazzjhm-unsplash_5

Angelini Pharma and JCR Pharmaceuticals partner to develop new epilepsy therapies

Angelini Pharma and JCR Pharmaceuticals have announced that they have entered into an exclusive global …

img_4190-e1376666350337-web

Epilepsy drug receives MHRA marketing authorisation

The MHRA has granted marketing authorisation (MA) for Ontozry (cenobamate) for the treatment of focal-onset …

Accure Therapeutics’ drug candidate can slow epilepsy progression, study shows

Accure Therapeutics, an R&D pharmaceutical company in the central nervous system (CNS) field, has announced …

Latest content